Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 6
2008 5
2009 6
2010 5
2011 7
2012 8
2013 5
2014 2
2015 1
2016 2
2017 1
2018 2
2020 1
2021 1
2023 2
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Among authors: inrig jk. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. Among authors: inrig jk. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Beware Intradialytic Hypotension: How Low Is Too Low?
Inrig JK. Inrig JK. Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1453-1454. doi: 10.2215/CJN.10150818. Epub 2018 Sep 20. Clin J Am Soc Nephrol. 2018. PMID: 30237217 Free PMC article. No abstract available.
Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis.
Mariani LH, Trachtman H, Thompson A, Gillespie BS, Denburg M, Diva U, Geetha D, Greasley PJ, Hladunewich MA, Huizinga RB, Inrig JK, Komers R, Laurin LP, Little DJ, Nachman PH, Smith KA, Walsh L, Gibson KL. Mariani LH, et al. Among authors: inrig jk. Am J Kidney Dis. 2025 May;85(5):610-617. doi: 10.1053/j.ajkd.2024.08.011. Epub 2024 Oct 23. Am J Kidney Dis. 2025. PMID: 39455047 Free PMC article. Review.
Mechanisms and Treatment of Intradialytic Hypertension.
Van Buren PN, Inrig JK. Van Buren PN, et al. Among authors: inrig jk. Blood Purif. 2016;41(1-3):188-93. doi: 10.1159/000441313. Epub 2016 Jan 15. Blood Purif. 2016. PMID: 26765312 Free PMC article. Review.
Blood pressure management.
Inrig JK. Inrig JK. Semin Dial. 2011 Sep-Oct;24(5):512-4. doi: 10.1111/j.1525-139X.2011.00958.x. Epub 2011 Aug 28. Semin Dial. 2011. PMID: 21883468 No abstract available.
50 results